The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease

Oncotarget

Volumn 6, Issue 5, 2015, Pages 2693-2708

  Patton, John T ^a   Lustberg, Mark E ^b   Lozanski, Gerard ^b   Garman, Sabrina L ^a   Towns, William H ^a   Drohan, Callie M ^a   Lehman, Amy ^b   Zhang, Xiaoli ^b   Bolon, Brad ^c   Pan, Li ^b   Kinghorn, A Douglas ^b   Grever, Michael R ^a   Lucas, David M ^a,b   Baiocchi, Robert A ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

EBV; Immunomodulation; Lymphoproliferative disease; Silvestrol

Indexed keywords

ANTINEOPLASTIC AGENT; CD8 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; FLUDARABINE; IMMUNOMODULATING AGENT; LATENT MEMBRANE PROTEIN 1; PROTEIN KINASE B; SILVESTROL; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN; STAT1 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; TRITERPENE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL TRANSFORMATION; COCULTURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG TARGETING; EFFECTOR CELL; ENZYME INHIBITION; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; LYMPHOBLASTOID CELL LINE; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; CYTOTOXICITY; DRUG EFFECTS; EPSTEIN BARR VIRUS; EPSTEIN-BARR VIRUS INFECTIONS; GENETICS; IMMUNOLOGY; LYMPHOPROLIFERATIVE DISORDERS; METABOLISM; PROTEIN SYNTHESIS; SCID MOUSE; TIME; TUMOR ASSOCIATED LEUKOCYTE; VIROLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; IMMUNITY, INNATE; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOPROLIFERATIVE DISORDERS; MICE, SCID; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TRITERPENES; VIRAL MATRIX PROTEINS;

EID: 84923307201     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2098     Document Type: Article

References (54)

1. Kieff E and Rickinson AB. (2001). Epstein-Barr Virus. In: Knipe DM HP, ed. Fields Virology. (Philadelphia: Lippincott Williams & Wilkins).
2. Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, Hwang IG, Park YH, Ahn JS, Jung CW, Kim K, Ahn YC, Kang WK, Park K and Kim WS. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood. 2007; 110(3):972-978.
3. Hwang BY, Su BN, Chai H, Mi Q, Kardono LB, Afriastini JJ, Riswan S, Santarsiero BD, Mesecar AD, Wild R, Fairchild CR, Vite GD, Rose WC, Farnsworth NR, Cordell GA, Pezzuto JM, et al. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J Org Chem. 2004; 69(10):3350-3358; ibid. 6156.
4. Kim S, Hwang BY, Su BN, Chai H, Mi Q, Kinghorn AD, Wild R and Swanson SM. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/ apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res. 2007; 27(4B):2175-2183.
5. Mi Q, Kim S, Hwang BY, Su BN, Chai H, Arbieva ZH, Kinghorn AD and Swanson SM. Silvestrol regulates G2/M checkpoint genes independent of p53 activity. Anticancer Res. 2006; 26(5A):3349-3356.
6. Cencic R, Carrier M, Trnkus A, Porco JA, Jr., Minden M and Pelletier J. Synergistic effect of inhibiting translation initiation in combination with cytotoxic agents in acute myelogenous leukemia cells. Leuk Res. 2010; 34(4):535- 541.
7. Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR and Marcucci G. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. J Hematol Oncol. 2013; 6:21.
8. Kogure T, Kinghorn AD, Yan I, Bolon B, Lucas DM, Grever MR and Patel T. Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer. PLoS One. 2013; 8(9):e76136.
9. Chambers JM, Lindqvist LM, Webb A, Huang DC, Savage GP and Rizzacasa MA. Synthesis of biotinylated episilvestrol: highly selective targeting of the translation factors eIF4AI/II. Org Lett. 2013; 15(6):1406-1409.
10. Sadlish H, Galicia-Vazquez G, Paris CG, Aust T, Bhullar B, Chang L, Helliwell SB, Hoepfner D, Knapp B, Riedl R, Roggo S, Schuierer S, Studer C, Porco JA, Jr., Pelletier J and Movva NR. Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A-RNA Complex. ACS Chem Biol. 2013.
11. Bordeleau ME, Robert F, Gerard B, Lindqvist L, Chen SM, Wendel HG, Brem B, Greger H, Lowe SW, Porco JA and Pelletier J. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest. 2008; 118:1-11.
12. Cencic R, Carrier M, Galicia-Vazquez G, Bordeleau ME, Sukarieh R, Bourdeau A, Brem B, Teodoro JG, Greger H, Tremblay ML, Porco JA, Jr. and Pelletier J. Antitumor activity and mechanism of action of the cyclopenta[b] benzofuran, silvestrol. PLoS One. 2009; 4(4):e5223.
13. Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, Davis ME, Rozewski DM, Johnson AJ, Su BN, Goettl VM, Heerema NA, Lin TS, Lehman A, Zhang X, Jarjoura D, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood. 2009; 113(19):4656-4666.
14. Alinari L, Prince CJ, Edwards RB, Towns WH, Mani R, Lehman A, Zhang X, Jarjoura D, Pan L, Kinghorn AD, Grever MR, Baiocchi RA and Lucas DM. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol. Clin Cancer Res. 2012; 18(17):4600-4611.
15. Rowe M, Young LS, Crocker J, Stokes H, Henderson S and Rickinson AB. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med. 1991; 173(1):147-158.
16. Baiocchi RA and Caligiuri MA. Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)- associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci U S A. 1994; 91(12):5577-5581.
17. Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, Hertlein E, Lustberg ME, Quinion C, Zhang X, Lozanski G, Muthusamy N, Praetorius-Ibba M, O'Connor OA, Goldenberg DM, Byrd JC, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011; 117(17):4530-4541.
18. Baiocchi RA, Ward JS, Carrodeguas L, Eisenbeis CF, Peng R, Roychowdhury S, Vourganti S, Sekula T, O'Brien M, Moeschberger M and Caligiuri MA. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. J Clin Invest. 2001; 108(6):887-894.
19. Godoy-Ramirez K, Makitalo B, Thorstensson R, Sandstrom E, Biberfeld G and Gaines H. A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry. Cytometry A. 2005; 68(2):71-80.
20. Helguera G, Rodriguez JA, Luria-Perez R, Henery S, Catterton P, Bregni C, George TC, Martinez-Maza O and Penichet ML. Visualization and quantification of cytotoxicity mediated by antibodies using imaging flow cytometry. J Immunol Methods. 2011; 368(1-2):54-63.
21. Mosier DE, Picchio GR, Baird SM, Kobayashi R and Kipps TJ. Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes. Cancer Res. 1992; 52(19 Suppl):5552s-5553s.
22. Saradhi UV, Gupta SV, Chiu M, Wang J, Ling Y, Liu Z, Newman DJ, Covey JM, Kinghorn AD, Marcucci G, Lucas DM, Grever MR, Phelps MA and Chan KK. Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry. AAPS J. 2011; 13(3):347-356.
23. Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, Pich D and Hammerschmidt W. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 1997; 16(20):6131-6140.
24. Najjar I, Baran-Marszak F, Le Clorennec C, Laguillier C, Schischmanoff O, Youlyouz-Marfak I, Schlee M, Bornkamm GW, Raphael M, Feuillard J and Fagard R. Latent membrane protein 1 regulates STAT1 through NFkappaB- dependent interferon secretion in Epstein-Barr virus-immortalized B cells. J Virol. 2005; 79(8):4936-4943.
25. Shair KH, Bendt KM, Edwards RH, Bedford EC, Nielsen JN and Raab-Traub N. EBV latent membrane protein 1 activates Akt, NFkappaB, and Stat3 in B cell lymphomas. PLoS Pathog. 2007; 3(11):e166.
26. Kenney JL, Guinness ME, Reiss M and Lacy J. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) sensitizes EBV-immortalized B cells to transforming growth factor-beta and chemotherapeutic agents. Int J Cancer. 2001; 91(1):89-98.
27. Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR, Heslop HE and Rooney CM. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003; 101(5):1905-1912.
28. Mei YP, Zhou JM, Wang Y, Huang H, Deng R, Feng GK, Zeng YX and Zhu XF. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle. 2007; 6(11):1379-1385.
29. Hannigan A and Wilson JB. Evaluation of LMP1 of Epstein-Barr virus as a therapeutic target by its inhibition. Mol Cancer. 2010; 9:184.
30. Yang L, Lu Z, Ma X, Cao Y and Sun LQ. A therapeutic approach to nasopharyngeal carcinomas by DNAzymes targeting EBV LMP-1 gene. Molecules. 2010; 15(9):6127- 6139.
31. Takada K, Horinouchi K, Ono Y, Aya T, Osato T, Takahashi M and Hayasaka S. An Epstein-Barr virusproducer line Akata: establishment of the cell line and analysis of viral DNA. Virus genes. 1991; 5(2):147-156.
32. Rowe M, Rooney CM, Edwards CF, Lenoir GM and Rickinson AB. Epstein-Barr virus status and tumour cell phenotype in sporadic Burkitt's lymphoma. Int J Cancer. 1986; 37(3):367-373.
33. Takada K. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int J Cancer. 1984; 33(1):27-32.
34. Gires O, Kohlhuber F, Kilger E, Baumann M, Kieser A, Kaiser C, Zeidler R, Scheffer B, Ueffing M and Hammerschmidt W. Latent membrane protein 1 of Epstein- Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 1999; 18(11):3064-3073.
35. Dawson CW, Tramountanis G, Eliopoulos AG and Young LS. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem. 2003; 278(6):3694-3704.
36. Kung CP and Raab-Traub N. Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3. J Virol. 2008; 82(11):5486-5493.
37. Kung CP, Meckes DG, Jr. and Raab-Traub N. Epstein-Barr virus LMP1 activates EGFR, STAT3, and ERK through effects on PKCdelta. J Virol. 2011; 85(9):4399-4408.
38. Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, Jankowska-Gan E, Burlingham WJ, Sun X, Gulley ML, Tang W, Gumperz JE and Kenney SC. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol. 2011; 85(1):165-177.
39. Huppa JB and Davis MM. T-cell-antigen recognition and the immunological synapse. Nature reviews Immunology. 2003; 3(12):973-983.
40. Ramsay AG, Johnson AJ, Lee AM, Gorgun G, Le Dieu R, Blum W, Byrd JC and Gribben JG. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. Journal of Clinical Investigation. 2008; 118(7):2427- 2437.
41. Wang D, Liebowitz D, Wang F, Gregory C, Rickinson A, Larson R, Springer T and Kieff E. Epstein-Barr Virus Latent Infection Membrane-Protein Alters the Human Lymphocyte-B Phenotype - Deletion of the Amino Terminus Abolishes Activity. Journal of Virology. 1988; 62(11):4173-4184.
42. Fuzzati-Armentero MT and Duchosal MA. hu-PBL-SCID mice: an in vivo model of Epstein-Barr virus-dependent lymphoproliferative disease. Histol Histopathol. 1998; 13(1):155-168.
43. Roychowdhury S, Baiocchi RA, Vourganti S, Bhatt D, Blaser BW, Freud AG, Chou J, Chen CS, Xiao JJ, Parthun M, Chan KK, Eisenbeis CF, Ferketich AK, Grever MR, Chen CS and Caligiuri MA. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr viruspositive lymphoproliferative disorder. Journal of the National Cancer Institute. 2004; 96(19):1447-1457.
44. Tary-Lehmann M, Saxon A and Lehmann PV. The human immune system in hu-PBL-SCID mice. Immunology today. 1995; 16(11):529-533.
45. Baiocchi RA, Ross ME, Tan JC, Chou CC, Sullivan L, Haldar S, Monne M, Seiden MV, Narula SK, Sklar J and et al. Lymphomagenesis in the SCID-hu mouse involves abundant production of human interleukin-10. Blood. 1995; 85(4):1063-1074.
46. Dojcinov SD, Venkataraman G, Pittaluga S, Wlodarska I, Schrager JA, Raffeld M, Hills RK and Jaffe ES. Agerelated EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood. 2011; 117(18):4726- 4735.
47. Bibas M and Antinori A. EBV and HIV-Related Lymphoma. Mediterranean journal of hematology and infectious diseases. 2009; 1(2):e2009032.
48. Cohen JI, Fauci AS, Varmus H and Nabel GJ. Epstein-Barr virus: an important vaccine target for cancer prevention. Science translational medicine. 2011; 3(107):107fs107.
49. Chen H, Hutt-Fletcher L, Cao L and Hayward SD. A positive autoregulatory loop of LMP1 expression and STAT activation in epithelial cells latently infected with Epstein- Barr virus. J Virol. 2003; 77(7):4139-4148.
50. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E and Gabrilovich DI. Chemotherapy enhances tumor cell susceptibility to CTLmediated killing during cancer immunotherapy in mice. J Clin Invest. 2010; 120(4):1111-1124.
51. Saijo N, Shimizu E, Shibuya M, Irimajiri N, Takizawa T, Eguchi K, Shinkai T, Tominaga K, Shimabukuro Z, Taniguchi T and Hoshi A. Effect of chemotherapy on natural-killer activity and antibody-dependent cell-mediated cytotoxicity in carcinoma of the lung. Br J Cancer. 1982; 46(2):180-189.
52. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakamoto M, Burioka N and Shimizu E. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007; 13(5):1552-1561.
53. Merlo A, Turrini R, Dolcetti R, Martorelli D, Muraro E, Comoli P and Rosato A. The interplay between Epstein- Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica. 2010; 95(10):1769-1777.
54. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods. 2001; 25(4):402- 408.